| Literature DB >> 34449722 |
Katherine M Laycock1, Leslie A Enane2, Andrew P Steenhoff1,3,4.
Abstract
Adolescents and young adults (AYA, ages 10-24 years) comprise a uniquely important but understudied population in global efforts to end tuberculosis (TB), the leading infectious cause of death by a single agent worldwide prior to the COVID-19 pandemic. While TB prevention and care strategies often overlook AYA by grouping them with either children or adults, AYA have particular physiologic, developmental, and social characteristics that require dedicated approaches. This review describes current evidence on the prevention and control of TB among AYA, including approaches to TB screening, dynamics of TB transmission among AYA, and management challenges within the context of unique developmental needs. Challenges are considered for vulnerable groups of AYA such as migrants and refugees; AYA experiencing homelessness, incarceration, or substance use; and AYA living with HIV. We outline areas for needed research and implementation strategies to address TB among AYA globally.Entities:
Keywords: adherence; retention in care; schools; screening; transmission; youth-friendly services
Year: 2021 PMID: 34449722 PMCID: PMC8396328 DOI: 10.3390/tropicalmed6030148
Source DB: PubMed Journal: Trop Med Infect Dis ISSN: 2414-6366
Risk Factors for TB Infection and Progression to Disease in Adolescents and Young Adults.
| Individual Factors | Community Factors |
|---|---|
|
Malnutrition Immunosuppression (e.g., HIV infection, use of immunomodulating biologic agents) Diabetes mellitus Obesity Smoking Harmful alcohol use |
Community prevalence of TB Overcrowded housing, schools, transit, and jails/prisons Air pollution |
TB Preventive Treatment Regimens Recommended by the World Health Organization for Adolescents and Young Adults [18].
| Medication (s) | Dosing Interval | Duration |
|---|---|---|
|
| ||
| Isoniazid monotherapy | Daily | 6 months (6H) or |
| Rifampicin monotherapy (4R) | Daily | 4 months |
| Rifampicin plus Isoniazid (3HR) | Daily | 3 months |
| Rifapentine plus Isoniazid | Weekly (3HP) | 3 months (12 doses) |
| Rifapentine plus Isoniazid | Daily (1HP) * | 1 month (28 doses) |
|
| ||
| Levofloxacin | Daily | 6 months |
* This regimen is recommended only for ages 13 years and older, as daily dosing of rifapentine has not yet been established in children and adolescents under age 13 years [18].
Figure 1Barriers to TB Care for Marginalized Adolescents and Young Adults.
Figure 2Public Health Priorities and Areas for Further Research and Implementation to Address TB among Adolescents and Young Adults.